Advanced in Cholangiocarcinoma (Bile Duct Cancer)

Tianqiang Z. Song

National Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine, Tianjin Key Laboratory Of Digestive Cancer, 
Tianjin, CN 
Advanced in Cholangiocarcinoma (Bile Duct Cancer)
National Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine, Tianjin Key Laboratory Of Digestive Cancer, 
Tianjin, CN 
OverviewLocationsClinical Research

Overview

Tianqiang Song practices in Tianjin, China. Song is rated as an Advanced expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Their top areas of expertise are Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, Hepato-Pancreato-Biliary Surgery, and Hepatectomy.

Their clinical research consists of co-authoring 159 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 13 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Locations

National Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine, Tianjin Key Laboratory Of Digestive Cancer, Tianjin, China
Other Locations
Guangzhou, 510275, China
Qixiangtai Road, Xiaobailou, 300070, China
Key Laboratory Of Cancer Prevention And Therapy, 3 Huanhu West Road, Dayingmen, 300060, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drug: ZW25 (Zanidatamab)
Study Phase: Phase 2
A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets
Study Phase: Phase 3
View 1 Less Clinical Trial

159 Total Publications

Survival benefit of adjuvant chemotherapy and individualized prognosis in resected cHCC-CCA.
Survival benefit of adjuvant chemotherapy and individualized prognosis in resected cHCC-CCA.
Journal: Bioscience trends
Published: July 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Song's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile